DNA vaccine containing VEGF-specific epitope and/or angiopoietin-2-specific epitope
US10543261B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 28, 2013 |
| Grant date | Jan 28, 2020 |
| Priority date | — |
| Expiry date | Aug 28, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2730/10143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of VEGF and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.